Arash Raoufinia

USPTO Granted Patents = 16 (Patent Applications = 18)

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 1.9

ph-index = 6

Forward Citations = 77(Granted Patents)

Location History:

McLean, VA (US) (2008 - 2010)
Springfield, VA (US) (2010 - 2013)
Vienna, VA (US) (2014 - 2022)

Company Filing History:

10 out of 78

Supernus Pharmaceuticals, Inc.

patents

5 out of 846

Otsuka Pharmaceutical Company, Limited

patents

1 out of 1

Supermus Pharmaceuticals, Inc.

patent

Years Active: 2008-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11400087 - Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function (2022-08-02),

2. 11344547 - Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function (2022-05-31),

3. 11154553 - Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function (2021-10-26),

4. 10980803 - Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function (2021-04-20),

5. 10525057 - Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function (2020-01-07),

6. 8709478 - Once daily formulations of tetracyclines (2014-04-29),

7. 8470364 - Once daily formulations of tetracyclines (2013-06-25),

8. 8394406 - Once daily formulations of tetracyclines (2013-03-12),

9. 8394405 - Once daily formulations of tetracyclines (2013-03-12),

10. 8206740 - Once daily formulations of tetracyclines (2012-06-26),

11. 7781449 - Trospium chloride treatment method (2010-08-24),

12. 7781448 - Once daily dosage forms of trospium (2010-08-24),

13. 7763635 - Once daily dosage forms of trospium (2010-07-27),

14. 7759359 - Method of treating bladder dysfunction with once-a-day trospium salt formulation (2010-07-20),

15. 7749532 - Once daily formulations of tetracyclines (2010-07-06),

Title: The Innovations of Arash Raoufinia

Introduction

Arash Raoufinia, based in Vienna, VA, is a notable inventor with a portfolio of 16 patents. His work primarily focuses on improving pharmacological treatments, demonstrating a commitment to innovation in the pharmaceutical industry.

Latest Patents

Among his latest contributions, Raoufinia has developed a method for providing aripiprazole to patients with impaired CYP2D6 or CYP3A4 enzyme function. The disclosed embodiments relate to strategies for initiating aripiprazole treatment in patients who are identified as poor metabolizers of these enzymes. This innovation aims to enhance treatment efficacy and safety for a specific patient demographic.

Career Highlights

Raoufinia has garnered experience working with reputable pharmaceutical companies, including Supernus Pharmaceuticals and Otsuka Pharmaceutical Company. His roles within these organizations have allowed him to refine his expertise in drug development and therapeutic methodologies.

Collaborations

Throughout his career, Raoufinia has collaborated with esteemed professionals such as Rong-Kun Chang and Niraj Shah. These partnerships have contributed to the advancement of innovative solutions within the pharmaceutical sector, fostering an environment of shared knowledge and growth.

Conclusion

Arash Raoufinia’s contributions to the field of pharmacology through his patents reflect his dedication to improving patient care. His innovative approaches to drug treatment continue to influence the pharmaceutical landscape, showcasing the importance of collaboration and creativity in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.